Should All Heart Failure Patients Be Treated With Sacubitril/Valsartan?

被引：0
作者：
Blankfield, Robert P. [1 ]
机构：
[1] Case Western Reserve Univ, Sch Med, Dept Family Med, North Royalton, OH USA
来源：
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS | 2018年 / 23卷 / 01期
关键词：
ANGIOTENSIN-NEPRILYSIN INHIBITION;
D O I：
10.1177/1074248417715006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：98 / 98
页数：1
相关论文
共 5 条
  • [1] Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
    McMurray, John J. V.
    Packer, Milton
    Desai, Akshay S.
    Gong, Jianjian
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Rouleau, Jean L.
    Shi, Victor C.
    Solomon, Scott D.
    Swedberg, Karl
    Zile, Michael R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) : 993 - 1004
  • [2] NICKLAS JM, 1992, NEW ENGL J MED, V327, P685
  • [3] Angiotensin Neprilysin Inhibition for Patients With Heart Failure What If Sacubitril/Valsartan Were a Treatment for Cancer?
    Packer, Milton
    [J]. JAMA CARDIOLOGY, 2016, 1 (09) : 971 - 972
  • [4] SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429
  • [5] EFFECT OF ENALAPRIL ON SURVIVAL IN PATIENTS WITH REDUCED LEFT-VENTRICULAR EJECTION FRACTIONS AND CONGESTIVE-HEART-FAILURE
    YUSUF, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (05) : 293 - 302
1